Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Liabilities and Shareholders Equity (2016 - 2025)

Avalo Therapeutics' Liabilities and Shareholders Equity history spans 12 years, with the latest figure at $116.5 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 22.74% year-over-year to $116.5 million; the TTM value through Dec 2025 reached $506.7 million, up 5.29%, while the annual FY2025 figure was $116.5 million, 22.74% down from the prior year.
  • Liabilities and Shareholders Equity reached $116.5 million in Q4 2025 per AVTX's latest filing, down from $125.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $150.7 million in Q4 2024 to a low of $21.0 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $78.3 million, with a median of $72.1 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 61.67% in 2022, then soared 618.01% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $80.2 million in 2021, then crashed by 58.4% to $33.4 million in 2022, then tumbled by 37.08% to $21.0 million in 2023, then skyrocketed by 618.01% to $150.7 million in 2024, then decreased by 22.74% to $116.5 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Liabilities and Shareholders Equity are $116.5 million (Q4 2025), $125.1 million (Q3 2025), and $126.6 million (Q2 2025).